Valuation: Autolus Therapeutics plc

Market Cap 56Cr 49Cr 45Cr 42Cr 78Cr 5.34TCr 80Cr 532.21Cr 208.89Cr 2.68TCr 210.88Cr 206.26Cr 8.86TCr P/E 2026 *
-2.61x
P/E 2027 * -3.42x
Enterprise Value 52Cr 45Cr 42Cr 39Cr 73Cr 4.97TCr 74Cr 494.74Cr 194.19Cr 2.49TCr 196.03Cr 191.74Cr 8.23TCr EV / Sales 2026 *
3.74x
EV / Sales 2027 * 3.17x
Free-Float
3.32%
Yield 2026 *
-
Yield 2027 * -
1 day+5.50%
1 week+41.61%
Current month+41.61%
1 month+31.06%
3 months+31.06%
6 months+48.59%
Current year+6.03%
1 week 1.61
Extreme 1.61
2.13
1 month 1.38
Extreme 1.38
2.13
Current year 1.18
Extreme 1.175
2.13
1 year 1.18
Extreme 1.175
2.52
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Chairman 61 01/10/2014
Director/Board Member 78 01/08/2014
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap.
29/06/26 Free

Director

79,167 0.0477%
18/03/26 Other

General Counsel

7,80,818 0.4700%
18/03/26 Other

Controller/Auditor

3,31,000 0.1992%
Change 5-day change 1-year change 3-year change Capi.($)
+5.50%+41.61%-10.21%-26.22% 56Cr
+1.59%+2.85%+40.11%+1.24% 7.83TCr
+2.77%+4.78%-1.65%+27.62% 5.11TCr
-0.84%+0.09%+20.92%+179.15% 4.92TCr
-0.13%+7.42%-50.22%-49.58% 4.47TCr
+0.80%+2.46%+62.77%-23.33% 3.07TCr
+1.84%+0.87%+54.17%+85.73% 2.44TCr
+9.86%+7.94%+122.36%-41.53% 2.36TCr
+4.29%+9.40%+3.77%+226.51% 2.1TCr
+1.66%-3.70%+65.40%+123.91% 1.66TCr
Average +2.73%+7.83%+30.74%+50.35% 3.4TCr
Weighted average by Cap. +1.89%+4.35%+26.87%+44.99%

Financials

2026 *2027 *
Net sales 14Cr 12Cr 11Cr 10Cr 19Cr 1.33TCr 20Cr 132.13Cr 52Cr 665.05Cr 52Cr 51Cr 2.2TCr 19Cr 17Cr 16Cr 14Cr 27Cr 1.83TCr 27Cr 182.36Cr 72Cr 917.87Cr 72Cr 71Cr 3.03TCr
Net income -22Cr -19Cr -18Cr -16Cr -30Cr -2.07TCr -31Cr -205.67Cr -81Cr -1.04TCr -81Cr -80Cr -3.42TCr -17Cr -15Cr -14Cr -13Cr -24Cr -1.64TCr -24Cr -163.37Cr -64Cr -822.32Cr -65Cr -63Cr -2.72TCr
Net Debt -3.95Cr -3.42Cr -3.19Cr -2.93Cr -5.51Cr -376.22Cr -5.6Cr -37Cr -15Cr -188.57Cr -15Cr -15Cr -623.41Cr 4.84Cr 4.19Cr 3.91Cr 3.59Cr 6.75Cr 460.75Cr 6.85Cr 46Cr 18Cr 230.94Cr 18Cr 18Cr 763.48Cr
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
07/26/07 $2.110 +5.50% 20,35,646
06/26/06 $2.000 +5.26% 37,90,151
05/26/05 $1.900 -2.56% 15,76,994
04/26/04 $1.950 +7.14% 42,09,870
03/26/03 $1.820 +22.15% 1,34,40,416
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.110USD
Average target price
8.675USD
Spread / Average Target
+311.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock